Wave Life Sciences Ltd. filings document a clinical-stage biotechnology company developing RNA medicines through the PRISM platform and Nasdaq-listed $0 par value ordinary shares under WVE. Its 8-K reports furnish operating and financial results, Regulation FD corporate presentations and material-event disclosures tied to clinical programs, regulatory communications and pipeline updates for oligonucleotide candidates including WVE-006 and WVE-007.
Proxy and governance filings cover shareholder voting matters, board and governance disclosures, material agreements, capital-structure information and risk factors. The company's formal disclosures also address clinical and regulatory risks, collaboration-related matters, financial condition, and the corporate controls associated with an RNA-medicines development business.
Wave Life Sciences Ltd. ownership disclosure: Adage Capital Management, L.P., together with Robert Atchinson and Phillip Gross, reports shared beneficial ownership of 1,000,000 Ordinary Shares, representing 0.53% of the class. The percentage is calculated using 188,254,954 Ordinary Shares outstanding as of February 19, 2026.
The filing states the shares are directly held by Adage Capital Partners, L.P., with shared voting and dispositive power reported by the named reporting persons. The business address for the reporting persons is 200 Clarendon Street, Boston, Massachusetts.
Wave Life Sciences Ltd. is asking shareholders to approve a redomiciliation that will make newly formed Wave Life Sciences, Inc., a Delaware corporation, the parent of the group. Each Wave-Singapore ordinary share will be exchanged on a one-for-one basis for Wave-Delaware common stock, which is expected to continue trading on Nasdaq under the symbol “WVE.”
The company cites closer alignment with its largely U.S.-based operations and shareholder base, as well as reduced duplicate regulatory, legal and reporting costs, as key reasons. A Singapore court–sanctioned Scheme of Arrangement requires approval by a majority in number of voting shareholders and at least 75% of shares voted at a June 22, 2026 special meeting in Cambridge, Massachusetts. Shareholders will not have appraisal rights under Singapore law, and the company intends that most holders will not recognize gain or loss for U.S. federal income tax purposes, though complex U.S., Singapore and U.K. tax consequences and potential changes in effective tax rate are highlighted as risks.
Wave Life Sciences Ltd reported that FMR LLC beneficially owns 5,192,761.43 shares of Common Stock, representing 2.8% of the class as reported on 03/31/2026. The filing states FMR LLC has sole voting power for 5,189,539 shares and sole dispositive power for 5,192,761.43 shares. The filing also notes that Abigail P. Johnson is reported with dispositive power over the same 5,192,761.43 shares. The schedule includes a statement that one or more other persons are known to have rights to dividends or sale proceeds, none exceeding 5%.
Wave Life Sciences Ltd. proposes to redomicile its parent from Singapore to Delaware via a Scheme of Arrangement. Under the plan, each issued Wave-Singapore ordinary share will be exchanged one-for-one for a newly issued share of Wave Life Sciences, Inc. (Wave-Delaware) common stock, which the company intends to list on Nasdaq under the symbol WVE. The Scheme requires shareholder approval at a Special Meeting convened by the Singapore Court and subsequent court sanction; it also remains subject to other Implementation Agreement conditions and a Long-Stop Date. The Board unanimously recommends a "FOR" vote. The proxy statement describes differences between Singapore and Delaware governance, potential tax (including Singapore stamp duty at 0.2%) and accounting treatment (common-control reorganization under U.S. GAAP), and implementation mechanics for equity awards, pre-funded warrants and transfer procedures.
Wave Life Sciences Ltd. filed an amendment to its annual report to provide detailed Part III information on directors, executive officers, governance and executive compensation for the year ended December 31, 2025. The company highlights a nine‑member board, fully independent key committees, and strong say‑on‑pay support.
The amendment describes 2025 business milestones across obesity, genetic liver and neuromuscular programs, a major collaboration with GSK, and a December 2025 equity financing that raised approximately $402.5 million, ending the year with $602.1 million in cash and cash equivalents. It also explains performance‑based cash bonuses, multi‑year option and RSU grants, and severance and change‑of‑control protections for senior leaders.
Wave Life Sciences reported first-quarter 2026 revenue of $38.2M, up from $9.2M a year earlier, mainly from its GSK collaboration, including recognition of remaining deferred revenue after regaining full rights to AATD candidate WVE-006.
Operating expenses rose to $69.5M, but the operating loss narrowed to $31.3M, and net loss improved to $26.1M or $0.13 per share, compared with a $46.9M loss or $0.29 per share a year ago.
Wave ended the quarter with $544.6M in cash and cash equivalents and expects this to fund operations for at least 12 months. The company highlighted progress across its RNA programs, including obesity candidate WVE-007, RNA editing programs WVE-006 and WVE-008, DMD therapy WVE-N531, and HD candidate WVE-003, and outlined plans to redomicile its parent entity from Singapore to Delaware.
Wave Life Sciences reported first quarter 2026 results and a broad pipeline update. Revenue rose to $38.2 million from $9.2 million a year earlier, while net loss narrowed to $26.1 million, or $0.13 per share, from $46.9 million.
Cash and cash equivalents were $544.6 million as of March 31, 2026, with an expected cash runway into the third quarter of 2028. The company highlighted progress for obesity candidate WVE-007, RNA editing program WVE-006 for AATD, liver disease program WVE-008, and exon 53 Duchenne therapy WVE-N531, with multiple data readouts and regulatory milestones targeted in 2026.
Wave Life Sciences Ltd. reported that its proposed redomiciliation of the group’s parent company from Singapore to the United States is progressing through the Singapore court process. The company has applied to the Singapore High Court to convene a shareholder meeting to vote on a Scheme of Arrangement under Section 210 of the Companies Act 1967.
The application, filed as case HC/OA 434/2026, is scheduled to be heard on April 29, 2026 at 10:00 am (Singapore Time). The court has set deadlines of 4:00 pm on April 22, 2026 for affidavits and 4:00 pm on April 24, 2026 for written submissions and bundles of authorities. The redomiciliation remains subject to approval by Wave shareholders and the Singapore High Court, and a definitive proxy statement with detailed information will be filed with the SEC and mailed or otherwise disseminated to shareholders.
Wave Life Sciences Ltd. Chief Medical Officer Christopher I. Wright filed an initial ownership report showing his equity position. He holds options over 300,000 ordinary shares at an exercise price of $5.94 expiring on May 27, 2035 and options over 273,750 ordinary shares at $12.75 expiring on February 5, 2036, all held directly. He also directly owns 45,625 ordinary shares. Footnotes explain that these options and restricted share units vest in stages between May 27, 2026 and February 8, 2030, contingent on his continued service with the company.
Wave Life Sciences Ltd. Chief Scientific Officer Erik Ingelsson filed an initial ownership report showing his current equity position in the company. He directly holds 87,864 ordinary shares, including 17,489 shares and time-based RSUs that vest in annual installments from February 8, 2027 through February 8, 2030, subject to his continued service.
Ingelsson also holds three option awards to purchase ordinary shares: 350,000 shares at an exercise price of $5.85 expiring on May 8, 2034; 200,000 shares at $11.74 expiring on February 4, 2035; and 273,750 shares at $12.75 expiring on February 5, 2036. Each option vests over several years, with 25% vesting on an initial date and the remainder vesting quarterly, conditioned on continued service.